TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis
Brief Summary: The purpose of this study is to compare the maintenance of mild to moderate ulcerative colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day versus placebo.


Options:
A: Arm Label: Rosiglitazone; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Rosiglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granulated mesalamine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulated mesalamine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Golimumab 1 milligram (mg) per kilogram (kg); Type: EXPERIMENTAL; Interventions: Drug: Golimumab 1 mg per kg | Arm Label: Golimumab 2 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 2 mg per kg | Arm Label: Golimumab 4 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 4 mg per kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Golimumab 1 mg per kg; Assigned to Arm(s): Golimumab 1 milligram (mg) per kilogram (kg) | Intervention Type: DRUG; Name: Golimumab 2 mg per kg; Assigned to Arm(s): Golimumab 2 mg per kg | Intervention Type: DRUG; Name: Golimumab 4 mg per kg; Assigned to Arm(s): Golimumab 4 mg per kg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Duloxetine 60 mg Once Daily Versus Placebo in Patients With Chronic Low Back Pain
Brief Summary: The purpose of this study is to determine if duloxetine reduces the severity of chronic low back pain.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Duloxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Duloxetine 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 120 mg, Duloxetine 20 mg, Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison
Brief Summary: LTBI Treatment is effective in prison


Options:
A: Arm Label: HIVneg/INH; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid (INH), Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX) | Arm Label: HIVneg/PL; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isoniazid Placebo (PL) | Arm Label: HIVpos/INH; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid (INH), Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX) | Arm Label: HIVpos/PL; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isoniazid Placebo (PL) | Intervention Type: DRUG; Name: Isoniazid (INH); Assigned to Arm(s): HIVneg/INH, HIVpos/INH | Intervention Type: DRUG; Name: Trimethoprim/Sulfamethoxazole (TMP/SMX); Assigned to Arm(s): HIVneg/INH, HIVpos/INH | Intervention Type: DRUG; Name: Isoniazid Placebo (PL); Assigned to Arm(s): HIVneg/PL, HIVpos/PL
B: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: isoniazid , randomized, open label, Drug: rifampin, randomized, open label | Intervention Type: DRUG; Name: isoniazid , randomized, open label; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: rifampin, randomized, open label; Assigned to Arm(s): 1
C: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifampin | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): A
D: Intervention Type: DRUG; Name: I ( isoniazid), II (isoniazid + rifampin ); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults
Brief Summary: The study will evaluate the effect of two intravenous dose regimens of benralizumab (MEDI-563) on the proportion of adult subjects with asthma exacerbations who required an urgent healthcare visit for treatment of an acute asthma exacerbation.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab (MILR1444A) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab (MILR1444A); Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Arm Label: Xolair; Type: EXPERIMENTAL; Interventions: Drug: omalizumab (Xolair), Drug: corticosteroids, Drug: long-acting beta-agonists | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: corticosteroids, Drug: long-acting beta-agonists | Intervention Type: DRUG; Name: omalizumab (Xolair); Assigned to Arm(s): Xolair | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: corticosteroids; Assigned to Arm(s): Xolair, placebo | Intervention Type: DRUG; Name: long-acting beta-agonists; Assigned to Arm(s): Xolair, placebo
C: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 0.3 mg/kg, Benralizumab 1.0 mg/kg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults
Brief Summary: The study will evaluate the effect of two intravenous dose regimens of benralizumab (MEDI-563) on the proportion of adult subjects with asthma exacerbations who required an urgent healthcare visit for treatment of an acute asthma exacerbation.


Options:
A: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Tezepelumab 700 mg; Type: EXPERIMENTAL; Interventions: Biological: Tezepelumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Tezepelumab; Assigned to Arm(s): Tezepelumab 700 mg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 0.3 mg/kg, Benralizumab 1.0 mg/kg
D: Arm Label: lebrikizumab - highest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - lowest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - middle dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - highest dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - middle dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - lowest dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Evaluation of Cosmetic Outcome and Surgical Site Infection Rates of Coated VICRYL* Plus Antibacterial (Polyglactin 910) Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery
Brief Summary: This is a 90-day study to evaluate cosmetic outcome and Surgical Site Infection in approximately 100 patients from 6 centers in China undergoing scheduled modified radical mastectomy for breast cancer.


Options:
A: Intervention Type: DEVICE; Name: wound closure device (Steri-Strip™); Assigned to Arm(s): N/A
B: Arm Label: Interrupted suturing Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Interrupted suturing | Arm Label: Subcuticular suturing Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Subcuticular suturing | Intervention Type: OTHER; Name: Interrupted suturing; Assigned to Arm(s): Interrupted suturing Group | Intervention Type: OTHER; Name: Subcuticular suturing; Assigned to Arm(s): Subcuticular suturing Group
C: Arm Label: Chinese Silk Suture; Type: ACTIVE_COMPARATOR; Interventions: Device: silk suture | Arm Label: VICRYL* Plus Suture; Type: EXPERIMENTAL; Interventions: Device: VICRYL* Plus suture | Intervention Type: DEVICE; Name: silk suture; Assigned to Arm(s): Chinese Silk Suture | Intervention Type: DEVICE; Name: VICRYL* Plus suture; Assigned to Arm(s): VICRYL* Plus Suture
D: Arm Label: Stainless Steel Staples; Type: ACTIVE_COMPARATOR; Interventions: Device: Stainless steel staples | Arm Label: 4-0 monofilament Sutures; Type: EXPERIMENTAL; Interventions: Device: 4-0 monofilament suture | Intervention Type: DEVICE; Name: 4-0 monofilament suture; Assigned to Arm(s): 4-0 monofilament Sutures | Intervention Type: DEVICE; Name: Stainless steel staples; Assigned to Arm(s): Stainless Steel Staples

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)
Brief Summary: The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to evaluate its safety, and to evaluate its effect on development of pulmonary hypertension, quality of life, and dyspnea (shortness of breath) symptoms in this participant population. Participants were randomized in a 2:1 ratio to receive ambrisentan or placebo, respectively. Participation in the study was to be up to 4 years, depending on how long it would take to enroll participants and observe study events. After randomization, visits to the clinic took place every 3 months, and laboratory procedures were performed every month.


Options:
A: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A
B: Arm Label: Part 1; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 2; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 3; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose | Intervention Type: DRUG; Name: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose; Assigned to Arm(s): Part 1, Part 2, Part 3 | Intervention Type: DRUG; Name: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently); Assigned to Arm(s): Part 1, Part 2
C: Arm Label: Ambrisentan; Type: EXPERIMENTAL; Interventions: Drug: Ambrisentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): Ambrisentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ambrisentan Verum; Type: EXPERIMENTAL; Interventions: Drug: Ambrisentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): Ambrisentan Verum | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Brief Summary: This randomized, controlled clinical trial, the Low Vision Depression Prevention TriAL (VITAL), will test the efficacy of collaborative low vision rehabilitation (LVR) to prevent depressive disorders in Age-Related Macular Degeneration (AMD). In this innovative intervention, a low vision occupational therapist collaborates with a low vision optometrist to develop and implement a care plan based on a subject's vision status, rehabilitation potential, and personal rehabilitation goals. An independent rater masked to treatment assignment will assess depressive disorders meeting DSM-IV criteria (primary outcome) and targeted vision function and vision-related quality of life (secondary outcomes) at baseline and then at 4 months to evaluate short-term effects (main trial end point) and at 12 months to evaluate long-term effects.


Options:
A: Arm Label: Citalopram; Type: EXPERIMENTAL; Interventions: Drug: 20mg daily citalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 20mg daily citalopram; Assigned to Arm(s): Citalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ICU Diaries; Type: EXPERIMENTAL; Interventions: Behavioral: ICU Diary | Arm Label: Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation | Arm Label: ICU Diary plus Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: ICU Diary, Behavioral: Psychoeducation | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ICU Diary; Assigned to Arm(s): ICU Diaries, ICU Diary plus Psychoeducation | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): ICU Diary plus Psychoeducation, Psychoeducation
C: Arm Label: BA-LVR; Type: EXPERIMENTAL; Interventions: Behavioral: BA-LVR | Arm Label: ST-LVR; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: ST-LVR | Intervention Type: BEHAVIORAL; Name: BA-LVR; Assigned to Arm(s): BA-LVR | Intervention Type: BEHAVIORAL; Name: ST-LVR; Assigned to Arm(s): ST-LVR
D: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Brief Summary: This randomized, controlled clinical trial, the Low Vision Depression Prevention TriAL (VITAL), will test the efficacy of collaborative low vision rehabilitation (LVR) to prevent depressive disorders in Age-Related Macular Degeneration (AMD). In this innovative intervention, a low vision occupational therapist collaborates with a low vision optometrist to develop and implement a care plan based on a subject's vision status, rehabilitation potential, and personal rehabilitation goals. An independent rater masked to treatment assignment will assess depressive disorders meeting DSM-IV criteria (primary outcome) and targeted vision function and vision-related quality of life (secondary outcomes) at baseline and then at 4 months to evaluate short-term effects (main trial end point) and at 12 months to evaluate long-term effects.


Options:
A: Arm Label: regular O&M-training; Type: ACTIVE_COMPARATOR; Interventions: Other: orientation and mobility training | Arm Label: standardised O&M-training; Type: EXPERIMENTAL; Interventions: Other: orientation and mobility training | Intervention Type: OTHER; Name: orientation and mobility training; Assigned to Arm(s): regular O&M-training, standardised O&M-training
B: Arm Label: BA-LVR; Type: EXPERIMENTAL; Interventions: Behavioral: BA-LVR | Arm Label: ST-LVR; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: ST-LVR | Intervention Type: BEHAVIORAL; Name: BA-LVR; Assigned to Arm(s): BA-LVR | Intervention Type: BEHAVIORAL; Name: ST-LVR; Assigned to Arm(s): ST-LVR
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Overground visual cue training; Type: EXPERIMENTAL; Interventions: Behavioral: Overground visual cue training | Arm Label: Treadmill visual cue training; Type: EXPERIMENTAL; Interventions: Behavioral: Treadmill visual cue training | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care | Intervention Type: BEHAVIORAL; Name: Overground visual cue training; Assigned to Arm(s): Overground visual cue training | Intervention Type: BEHAVIORAL; Name: Treadmill visual cue training; Assigned to Arm(s): Treadmill visual cue training
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Low Vision Intervention - Outpatient Training Program | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Vision Intervention - Outpatient Training Program; Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Brief Summary: This randomized, controlled clinical trial, the Low Vision Depression Prevention TriAL (VITAL), will test the efficacy of collaborative low vision rehabilitation (LVR) to prevent depressive disorders in Age-Related Macular Degeneration (AMD). In this innovative intervention, a low vision occupational therapist collaborates with a low vision optometrist to develop and implement a care plan based on a subject's vision status, rehabilitation potential, and personal rehabilitation goals. An independent rater masked to treatment assignment will assess depressive disorders meeting DSM-IV criteria (primary outcome) and targeted vision function and vision-related quality of life (secondary outcomes) at baseline and then at 4 months to evaluate short-term effects (main trial end point) and at 12 months to evaluate long-term effects.


Options:
A: Arm Label: BA-LVR; Type: EXPERIMENTAL; Interventions: Behavioral: BA-LVR | Arm Label: ST-LVR; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: ST-LVR | Intervention Type: BEHAVIORAL; Name: BA-LVR; Assigned to Arm(s): BA-LVR | Intervention Type: BEHAVIORAL; Name: ST-LVR; Assigned to Arm(s): ST-LVR
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary Low Vision Service | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Basic Low Vision Service | Intervention Type: OTHER; Name: Interdisciplinary Low Vision Service; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Basic Low Vision Service; Assigned to Arm(s): Arm 2
C: Arm Label: Visual Reconstitution Therapy; Type: EXPERIMENTAL; Interventions: Other: Visual Reconstitutions Therapy | Arm Label: Saccadic Eye Movement Training; Type: ACTIVE_COMPARATOR; Interventions: Other: Saccadic Eye Movement Training | Intervention Type: OTHER; Name: Visual Reconstitutions Therapy; Assigned to Arm(s): Visual Reconstitution Therapy | Intervention Type: OTHER; Name: Saccadic Eye Movement Training; Assigned to Arm(s): Saccadic Eye Movement Training
D: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser

Answer: A